Stock is my life
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
1.67 SRPX - 2.5 times AV Vol of 9.4K
All Pinks are like this - Why complain ?
Twice average vol of 10K at 24K
SRPX 1.67 on fire
Pivot Point 2nd Level Resistance
1.7033
Pivot Point 1st Level Resistance
1.6767
SRPX on FIRE
Resistance points :
Pivot Point 2nd Level Resistance
1.7033
Pivot Point 1st Level Resistance
1.6767
SRPX :
Pivot Point 2nd Level Resistance
1.7033
Pivot Point 1st Level Resistance
1.6767
Pivot Point 2nd Level Resistance
1.7033
Pivot Point 1st Level Resistance
1.6767
SRPX 1.66 now Target $15 of May 2011
Yeh Baby SRPX !
News ! SRPX 1.65 (Target $15 of May)
SRPX 1.65 ASk getting slapped Target $15
SRPX had hit $15 last May
SRPX 1.65 from the 1.20s Target $15 of May 2011 plus fresh News today!
What a stock from 7s to 30s
So have been the Coffee stocks like JVA
SRPX 1.65
SRPX Huge NEws 1.65 - Target $15
Wohoo SRPX 1.65 - $15 baby
1.64 now
News ! SRPX 1.64 - Run to the last run of $15
Hope it runs Beyond $15 I will not complain lol
NEWS - Plus SRPX from 1.25 to 1.63 of late - It touched $15 recently
Yep SRPX is on FIRE of late with News today ! Easy $10
SRPX is climbing back up from 1.25 to 1.63 ! High was 15 recently !
I am expecting a break of 0.086 soon to the next levels of 0.15 and more. I am in at 0.04 to 0.05 levels with 250K !
Of course ! Don;t U know In Jan what happened ? 0.20 - Needs to break 0.086
VPRO - Pharma-Biotech Allies Driving the Global Biosimilars Industry (Viropro - 7/7/2011)
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
VPRO - Pharma-Biotech Allies Driving the Global Biosimilars Industry (Viropro - 7/7/2011)
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
VPRO - Pharma-Biotech Allies Driving the Global Biosimilars Industry (Viropro - 7/7/2011)
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
VPRO - Pharma-Biotech Allies Driving the Global Biosimilars Industry (Viropro - 7/7/2011)
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
Wasn't that difficult really - Google Viropro and go to News and sort by hour, week etc
VPRO.PK - Pharma-Biotech Allies Driving the Global Biosimilars Industry - 7/7/2011
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
7/7 : VPRO.PK - Pharma-Biotech Allies Driving the Global Biosimilars Industry
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
7/7 : VPRO - Pharma-Biotech Allies Driving the Global Biosimilars Industry
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
7/7 : VPRO - Pharma-Biotech Allies Driving the Global Biosimilars Industry
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
7/7 : VPRO - Pharma-Biotech Allies Driving the Global Biosimilars Industry
http://www.sbwire.com/press-releases/sbwire-99675.htm
As per our new research report “Global Biosimilars Market Analysis”, biotech and pharma sectors have teamed up to co-launch their biosimilars related initiatives. Recently, Spectrum Pharmaceuticals and Viropro decided to work together to develop a biosimilar of Roche/Genentech’s rituximab. Besides, Biocon and Pfizer entered into an agreement for the worldwide commercialization of Biocon’s biosimilar versions of insulin and insulin-analog products for diabetes: Recombinant Human Insulin, Glargine, Aspart, and Lispro.
Further, more and more drugmakers are realizing the potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. For instance, Watson Pharmaceuticals entered an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals to develop and commercialize Itero's biosimilar for the treatment of female infertility. Besides, Amgen has considered entering the "biosimilars" space, particularly in emerging markets like Asia and South America.
Further, we have done thorough research and prudent analysis of the global biosimilars market and identified some critical factors acting as a catalyst for the industry’s current and future growth outlook. The report reveals that, the global biosimilars market is anticipated to grow at a CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming patent expiries and the rising drugs bill that will encourage payers to address the barriers to biosimilars access to control costs. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
The report reveals that, as many biologic patents are in the way to face expirations in the coming years, it is expected that many private players will pour in their investments as well as their interests in developing biosimilars versions. Besides, considerable positive regulatory developments will be observed in the sector that will be a result of the mounting pressure from governments, insurers and patients groups to reduce costs.
“Global Biosimilars Market Analysis” provides extensive information and rational analysis of the global biosimilars market. It has thoroughly examined current market drivers & restraints, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in coming years. The report also provides an insight into different biosimilars marketed products along with country-wise analysis to present an overview of the developments taking place in the global biosimilars industry. Further, a review of product introductions/innovations and recent industry activity has been covered in the report.
VPRO to 0.06. Once the 0.06 barrier breaks next resistance at 0.086
Tough one to break - We need more of the 1.4M vol days like a few days back
VPRO 0.06
http://www.smallcapnetwork.com/Two-Outta-Three-Isnt-Bad-ZLCS-VPRO-and-WZE-in-Focus/s/via/1789/article/view/p/mid/2/id/5/
If you're like even the most enthusiastic of small cap aficionados, you've probably never heard of Viropro. That's ok. Though VPRO has been trading for years, it's only been effectively trading (on any meaningful volume) since the beginning of this year. That's when the company, aka Alpha Biologics after a name change last month, inked a deal with Spectrum Pharmaceuticals to do for the what it 'does'...which is offer technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases. Now, if you know what that means simply from reading it one time, get a life. For the rest of us, it means that Viropro Inc. helps other biopharma companies make drugs to use in their own pre-clinical, Phase1, and clinical trials.
Anyway, though it's been erratic to be sure, VPRO has also been taking two steps forward and one step back on a pretty reliable basis since January. The result is the development of a rising support line (purple), and a near-term horizontal ceiling at $0.06. If that level, and then the $0.086 mark can be knocked over, Viropro could take off. I'd rather be in this small cap stock before then though
VPRO upto 0.06